Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Large Intestinal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Intestinal Neoplasm
Large Intestinal Neoplasm

Subtype

Large Intestinal Neoplasm

CI-CAN-00001062Explore in graph →

Non-malignant1,846 active trials21 approved drugs383 evidence items

NCIt: C215201

Overview
Statistics
Survival
Genomics27
Variants & evidence383
Drugs80
Trials8846
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (370)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 251–275 of 370 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
· J Clin Oncol · 2008 · PMID 19001320 · validated civic_curation pubmed
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer.
· Br J Cancer · 2009 · PMID 19603024 · validated civic_curation pubmed
BRAF mutation in metastatic colorectal cancer.
· N Engl J Med · 2009 · PMID 19571295 · validated civic_curation pubmed
The DCC protein and prognosis in colorectal cancer.
· N Engl J Med · 1996 · PMID 8929264 · validated civic_curation pubmed
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
· Invest New Drugs · 2016 · PMID 26666244 · validated civic_curation pubmed
Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
· Lancet Gastroenterol Hepatol · 2016 · PMID 28404093 · validated civic_curation pubmed
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
· Cancer Res · 2009 · PMID 19223544 · validated civic_curation pubmed

Showing 251–275 of 370 publications

← Previous
1
…
10
11
12
…
15
Next →

PIK3CA mutations predict local recurrences in rectal cancer patients.

· Clin Cancer Res · 2009 · PMID 19903786 · validated civic_curation pubmed

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.

· Lancet Oncol · 2019 · PMID 30857956 · validated civic_curation pubmed

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· Target Oncol · 2020 · PMID 33068284 · validated civic_curation pubmed

Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study.

· JCO Precis Oncol · 2022 · PMID 36315917 · validated civic_curation pubmed

Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2022 · PMID 36409971 · validated civic_curation pubmed

Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review.

· Clin Cancer Res · 2012 · PMID 22357840 · validated civic_curation pubmed

Prediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.

· BMC Cancer · 2015 · PMID 26508446 · validated civic_curation pubmed

Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.

· Mol Clin Oncol · 2015 · PMID 26623049 · validated civic_curation pubmed

A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer.

· Int J Cancer · 2016 · PMID 26152787 · validated civic_curation pubmed

Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.

· Int J Clin Exp Pathol · 2015 · PMID 25973082 · validated civic_curation pubmed

Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.

· Med Oncol · 2013 · PMID 23579861 · validated civic_curation pubmed

Patients with colorectal tumors with microsatellite instability and large deletions in HSP110 T17 have improved response to 5-fluorouracil–based chemotherapy.

· Gastroenterology · 2014 · PMID 24512910 · validated civic_curation pubmed

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

· J Clin Oncol · 2015 · PMID 26392102 · validated civic_curation pubmed

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.

· Br J Cancer · 2013 · PMID 23348520 · validated civic_curation pubmed

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

· J Clin Oncol · 2007 · PMID 17470858 · validated civic_curation pubmed

Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.

· Sci Rep · 2015 · PMID 26621817 · validated civic_curation pubmed

A multigene mutation classification of 468 colorectal cancers reveals a prognostic role for APC.

· Nat Commun · 2016 · PMID 27302369 · validated civic_curation pubmed

Regorafenib in metastatic colorectal cancer.

· Expert Rev Anticancer Ther · 2014 · PMID 24559322 · validated civic_curation pubmed